The Biotech Growth Trust (LON:BIOG) Stock Price Down 2.2% - Time to Sell?

Key Points

• The Biotech Growth Trust (LON:BIOG) shares fell by 2.2%, trading around GBX 1,090 ($14.56), which is down from a previous close of GBX 1,115 ($14.90).
• The stock has a market capitalization of £251.60 million and a significantly negative P/E ratio of -4.16, indicating potential profitability challenges.
• Insider Julie Tankard bought 369 shares at GBX 1,072 per share, suggesting some confidence from company insiders despite recent price declines.

The Biotech Growth Trust PLC (LON:BIOG - ) traded down 2.2% on Wednesday . The company traded as low as GBX 1,087.55 ($14.53) and last traded at GBX 1,090 ($14.56). 158,635 shares changed hands during trading, an increase of 11% from the average session volume of 142,898 shares. The stock had previously closed at GBX 1,115 ($14.90).

The Biotech Growth Trust Trading Down 2.2%

The business's 50 day simple moving average is GBX 965.89 and its two-hundred day simple moving average is GBX 819.28. The stock has a market cap of £251.60 million, a P/E ratio of -4.16 and a beta of 0.50. The company has a quick ratio of 0.00, a current ratio of 0.59 and a debt-to-equity ratio of 11.02.

Insider Activity at The Biotech Growth Trust

In other The Biotech Growth Trust news, insider Julie Tankard purchased 369 shares of the business's stock in a transaction dated Wednesday, October 15th. The shares were bought at an average price of GBX 1,072 per share, for a total transaction of £3,955.68. Company insiders own 1.50% of the company's stock.

About The Biotech Growth Trust

The Biotech Growth Trust seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. Performance is measured against the NASDAQ Biotechnology Index (sterling adjusted).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.